Mechanism

Evidence tier: 4 — Enzyme-inhibition mechanism characterized in vitro and in rodent metabolic models; downstream clinical effects measured only in animal studies. No human RCT data.

5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule selective inhibitor of nicotinamide N-methyltransferase (NNMT). NNMT is a cytosolic enzyme that catalyzes the transfer of a methyl group from S-adenosyl-L-methionine (SAM) to nicotinamide, producing N1-methylnicotinamide and S-adenosylhomocysteine. This reaction consumes both the methyl donor and the NAD+ precursor, and elevated NNMT activity in adipose tissue and liver has been linked to obesity, insulin resistance, and metabolic dysfunction.

The proposed mechanism operates on two metabolic axes. Increased NAD+ availability: NNMT inhibition reduces nicotinamide consumption, conserving the NAD+ precursor pool and potentially raising NAD+ levels in tissues with high NNMT activity. Improved methyl-donor economy: NNMT inhibition reduces SAM consumption, conserving methyl-donor capacity for other methylation reactions (DNA methylation, neurotransmitter synthesis, polyamine metabolism). The combined effect in NNMT-overexpressing tissues is thought to improve adipocyte metabolism, reduce fat storage, and enhance metabolic-rate-related parameters.

The foundational paper, Kraus 2014 in Nature (PMID 24717514), established that NNMT knockdown in adipose tissue protected mice from diet-induced obesity, with reduced adipocyte size and improved metabolic profile. This work motivated the development of small-molecule NNMT inhibitors including 5-amino-1MQ.

5-Amino-1MQ is a small molecule, not a peptide. Its inclusion in peptide-research directories reflects its place in the broader peptide-adjacent metabolic and longevity-research marketplace rather than its molecular biology. Mechanism remains preclinical — no human in-vivo NAD+ or methylation studies have measured the predicted downstream effects at clinically used doses.

Typical protocols

Evidence tier: 5 — No human RCTs. Protocols are mouse-model-derived extrapolations or community-evolved.

There are no published human clinical trials of 5-amino-1MQ as of May 2026. Frame protocols accordingly.

The Neelakantan 2018 mouse work (PMID 29155147) used 20 mg/kg subcutaneously per injection, three times per day, for 11 days — an aggressive dosing regimen in animal-pharmacology terms. Translation of this dose to humans without intermediate pharmacokinetic and safety work is not validated.

Community-circulated human protocols typically describe 50-150 mg orally per day taken in the morning, with cycles of 4-12 weeks. The oral route is preferred over subcutaneous given the molecule's small-molecule oral bioavailability profile. These protocols are not RCT-validated and the dose-response curve in humans is uncharacterized.

The honest framing: there is no validated human dose, no validated route, no validated cycling pattern. Specific dosing numbers circulating in metabolic-research communities are unsupported by clinical evidence. Patients considering 5-amino-1MQ should treat this as a pre-clinical research compound rather than a usable therapeutic.

Evidence by indication

Evidence tier: 3 — Rodent metabolic-model evidence; zero human RCT evidence.

Diet-induced obesity (mouse, Kraus 2014 / Neelakantan 2018): The Kraus 2014 Nature paper (PMID 24717514) established the mechanistic case for NNMT inhibition as a metabolic intervention. Neelakantan 2018 (PMID 29155147) showed that 5-amino-1MQ specifically reversed diet-induced obesity in mice, with reduced body weight, white adipose mass, and adipocyte size after 11 days of dosing.

Microbiome effects (mouse, 2022): Additional mouse work has shown 5-amino-1MQ combined with calorie restriction establishes a distinct gut microbiome profile in diet-induced obese mice, with implications for the metabolic-effect mechanism.

NAD+ and longevity-related mechanisms: The hypothesized NAD+-conservation mechanism overlaps conceptually with the broader NAD+-supplementation longevity literature (NR, NMN, NAD+ infusions). Whether 5-amino-1MQ produces meaningful changes in tissue NAD+ levels at tolerable human doses is empirically unknown.

Cancer (preclinical): NNMT is overexpressed in several cancers, and NNMT inhibition has been explored as a cancer-cell-metabolism intervention in preclinical models. This is a separate research line from the obesity/metabolism work.

Human evidence: None. 5-Amino-1MQ has not entered formal clinical development as of 2026. There is no IND, no Phase 1 trial, no FDA designations.

The honest framing: 5-amino-1MQ has interesting rodent metabolic data and a mechanistically plausible hypothesis, but the molecule is pre-clinical and there is no human evidence for any indication. The frequent marketing of 5-amino-1MQ as a "fat-loss peptide" overstates both its molecular identity (it is a small molecule, not a peptide) and the strength of the evidence (it is a research compound, not a validated therapeutic).

Safety profile

Evidence tier: 4 — Rodent safety data over short-duration treatment; zero human safety characterization.

In Neelakantan 2018 and subsequent mouse work, 5-amino-1MQ was generally well-tolerated at the studied doses with no documented acute toxicity. The molecule has not been systematically dose-escalated in any species for chronic-toxicity characterization. There is no human safety data.

Theoretical concerns include:

1. Off-target effects on other methyltransferases: Small-molecule selectivity vs other SAM-dependent enzymes has been characterized in vitro but may differ in vivo at chronic-dosing concentrations. 2. NAD+ pathway perturbation: Sustained inhibition of nicotinamide methylation could have unintended consequences on the broader NAD+ salvage and de-novo synthesis pathways. 3. Hepatic metabolism: NNMT is highly expressed in liver; chronic inhibition may have hepatic effects that are not characterized in any model. 4. Methylation balance: The methyl-donor-conservation effect could perturb other methylation-dependent processes (DNA methylation, neurotransmitter metabolism, homocysteine metabolism). 5. Research-supplier purity and identity: The molecule is not produced under GMP for any clinical-trial program, and research-supplier sourcing varies in purity.

The absence of human safety data is the central concern. Patients considering 5-amino-1MQ should treat it as a research compound with unknown human safety profile rather than a validated supplement.

Where it fits relative to alternatives

Evidence tier: 5 — Editorial positioning.

In the weight-loss and metabolic-intervention landscape:

Semaglutide (Wegovy, FDA-approved): ~15% weight loss, RCT-grade
Tirzepatide (Zepbound, FDA-approved): ~22% weight loss, RCT-grade
Retatrutide (Phase 3): ~24-29% weight loss
CagriSema (Phase 3 complete): ~22.7% weight loss
NAD+ precursor supplements (NR, NMN): widely available, modest human data on biomarkers, no significant weight-loss effect demonstrated
5-Amino-1MQ: Preclinical only, no human data

5-Amino-1MQ's position is research-context exploration of NNMT inhibition as a metabolic intervention. For patients seeking weight loss, the FDA-approved GLP-1-class options are categorically better-evidenced. For patients interested in NAD+ pathway modulation as a longevity intervention, NR and NMN have at least some human pharmacokinetic and biomarker data — though neither has demonstrated meaningful longevity benefits in humans.

There is no clinical scenario where 5-amino-1MQ is the preferred choice for weight loss or metabolic intervention in 2026 — the evidence base supports neither efficacy nor safety claims in human use.

Regulatory status + access

Evidence tier: 5 — Regulatory-process content.

5-Amino-1MQ is not FDA-approved for any indication, not on the FDA bulks list for 503A or 503B compounding (it is a small molecule, not a peptide, and falls outside the typical peptide-compounding scope), and is not lawfully available through US compounding pharmacy channels. The molecule has not entered formal clinical development — no IND, no Phase 1 trial. It is supplied through research-supplier channels and through some "research compound" wellness vendors. WADA does not list 5-amino-1MQ specifically. Patients considering 5-amino-1MQ for weight loss or metabolic-intervention purposes should discuss the absence of human data with a clinician and consider the FDA-approved GLP-1-class options as a categorically better-evidenced path.

References

Kraus D, Yang Q, Kong D, et al. 2014. Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nature. PMID 24717514
Neelakantan H, Vance V, Wetzel MD, et al. 2018. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochem Pharmacol. PMID 29155147
Wilding JPH, Batterham RL, Calanna S, et al. 2021. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. PMID 33567185 — cited as RCT-grade weight-loss alternative.

Limitations

This page does not constitute medical advice. 5-Amino-1MQ sits in a pre-clinical research-context category with no human trials, no human safety data, no characterized human dose-response, and no FDA-approved pathway. Patients pursuing 5-amino-1MQ through research-supplier channels are operating outside any clinical evidence base, and the molecule should not be framed as a treatment for obesity, metabolic dysfunction, or any specific indication. The frequent characterization of 5-amino-1MQ as a "peptide" in popular literature is inaccurate — it is a small molecule, and its inclusion in peptide-research directories reflects market context rather than molecular biology. Patients with obesity should pursue evaluation with a clinician and discussion of FDA-approved GLP-1-class options. We would update our framing if 5-amino-1MQ enters formal clinical development, if a Phase 1 trial reads out, or if rigorous human safety and pharmacokinetic data become available.

5-Amino-1MQ